Worth reading
91Important
Scored from 2 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
125
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationSecond quarter of the fiscal year ending October 20262 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,775 million-2.5%
Operating profit¥125 million+636.3%
Ordinary income¥115 million+510.4%
Net income¥71 million+537.2%
Gross Profit Margin58.8 %
Operating profit margin7.1 %
Selling, general and administrative expenses¥919 million
Results for the three months of the current quarter
Net Sales
¥915 million+6.5%
Operating profit
¥66 million+10.8%
Ordinary income
¥56 million-6.1%
Net income
¥37 million+11.8%
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales51.9%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Higher revenue from management support services for orthopedic practices¥32 million
- Decline following the surge in orders in the second quarter of the previous fiscal year¥-6 million
- Self-pay treatment-focused¥-21 million
- Hybrid¥57 million
- Exosome-related¥-18 million
- FatBank¥-13 million
Key KPIsA metric the company considers important as a management benchmark.
- KPI12,183Year on year against the same period last year+166
- KPI29,596Year on year against the same period last year+0.2%
- KPI3518Year on year against the same period last year-28.7%
- KPI44,300
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending October 2026 |
| Net Sales | ¥1,775 million (YoY -2.5%) |
| Operating profit | ¥125 million (YoY +636.3%) |
| Ordinary income | ¥115 million (YoY +510.4%) |
| Net income | ¥71 million (YoY +537.2%) |
| Gross Profit Margin | 58.8 % |
| Operating profit margin | 7.1 % |
| Selling, general and administrative expenses | ¥919 million |
| Results for the three months of the current quarter | Net Sales ¥915 million (YoY +6.5%) / Operating profit ¥66 million (YoY +10.8%) / Ordinary income ¥56 million (YoY -6.1%) / Net income ¥37 million (YoY +11.8%) |
| Progress against full-year forecast | Net Sales 51.9% |
| Breakdown of Factors Affecting the Change | Factors Higher revenue from management support services for orthopedic practices / Amount ¥32 million, Factors Decline following the surge in orders in the second quarter of the previous fiscal year / Amount ¥-6 million, Factors Self-pay treatment-focused / Amount ¥-21 million, Factors Hybrid / Amount ¥57 million, Factors Exosome-related / Amount ¥-18 million, Factors FatBank / Amount ¥-13 million |
| Key KPIs | KPI1 2,183, KPI2 9,596, KPI3 518, KPI4 4,300 |
Items this document does not state (18)
Full-year earnings forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue benefited from higher sales generated by management support services for orthopedic practices, but was affected by a decline following the surge in orders in the second quarter of the previous fiscal year. The main components of revenue are shown as self-pay treatment-focused, hybrid, exosome-related and FatBank, with their respective increases and decreases. On the profit side, improvements in the gross profit margin and fluctuations in expense items are shown, but not all factors can be identified from the legible portions of the text alone.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.